EurekaAlert. The drug, tisotumab vidotin, TV for short, releases a toxic substance from within the cancer cell to kill it.
It has been shown to be effective in certain drug-resistant tumors.
According to the article, researchers saw responses "...in 27 per cent of patients with bladder cancer, 26.5 per cent with cervical cancer, 14 per cent ovarian cancer, 13 per cent with oesophageal, 13 per cent with non-small cell lung and 7 per cent with endometrial cancer (although not in any men with prostate cancer). Responses lasted an average of 5.7 months, and up to 9.5 months in some patients."
The article was originally published in Lancet Oncology.